论文信息 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study - 字舞流文

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

M. Dimopoulos | H. Einsele | P. Sonneveld | M. Boccadoro | L. Baldini | A. Oriol | P. Moreau | A. Symeonidis | E. Katodritou | E. Terpos | M. Kosh | N. Tran | M. Mateos | Ioannis Orfanidis | R. Carson | S. Delimpasi | J. Bila | T. Kampfenkel | Weiping Liu | M. Beksaç